PREVIEW: Merck & Co Inc (MRK) earnings due 03/Feb at 11:30GMT/06:30EST

Merck & Co Inc (MRK) Q4 2021 (USD): EPS (exp. 1.53/1.33 GAAP), Revenue (exp. 13.16bln)

KEY PHARMA SALES:

• Keytruda /MK-3475: (exp. 4.64bln)
• Gardasil/Gardasil 9: (exp. 1.4bln)
• Molnupiravir/MK-4482: (exp. 1.37bln)
• Januvia: (exp. 1.04bln)
• Proquad: (exp. 0.5bln)

REVENUE SEGMENTS:

• Animal Health: (exp. 1.36bln)
• Cardiovascular: (exp. 174.50mln)
• Diabetes: (exp. 1.31bln)
• Hospital Acute Care: (exp. 1.01bln)
• Immunology: (exp. 285.00mln)
• Neuroscience: (exp. 85.00mln)
• Oncology: (exp. 5.20bln)
• Other: (exp. 89.33mln)
• Other Pharma Sales: (exp. 560.50mln)
• Pharmaceutical: (exp. 12.94bln)
• Vaccines: (exp. 2.72bln)
• Virology: (exp. 1.20bln)

DIVIDEND:

• Qtrly Dividend: (exp. 0.67)
• FY Dividend: (exp. 2.61)

EPS GUIDANCE:

• Q1 2022 EPS View: (exp. 2.16/2.14 GAAP)
• FY 2022 EPS View: (exp. 8.15/7.81 GAAP)

REVENUE GUIDANCE:

• Q1 2022 Revenue View: (exp. 13.91bln)
• FY 2022 Revenue View: (exp. 50.18bln)

INDEX WEIGHT:

• 0.5% SPX weight
• 1.5% Dow weight
• Sector/Industry: Health Care/Pharmaceuticals

BROKER RATING:

• Avg Rating: 'Buy'
• Avg Price Target: USD 92.90
• Price Target Changes (last 30 days): 4 upward vs 8 downward